**Supplementary Table 1.** Demographic and clinical factors evaluated in univariate analysis

|  |
| --- |
| *Baseline demographic and clinical factors:** Sex
* Age group
* Race
* Ethnicity
* Geographic region
* Height at baseline
* Weight at baseline
* BMI at baseline
* Primary reason for ESRD
* Type of dialysis (HD or PD)
* Time from first dialysis
* Dialysis adequacy

*Phosphate binder treatment-related factors:** Treatment (sucroferric oxyhydroxide or sevelamer)
* Maximum phosphate binder dose received
* Average daily number of PB tablets taken
* Average daily PB dose

*Concomitant medications:** Concomitant active vitamin D use (yes/no)
* Concomitant cinacalcet use (yes/no)

*Baseline serum levels of the following laboratory parameters:** Phosphorus
* FGF-23
* Intact PTH
* Corrected calcium
* Ionized calcium
* Total calcium
* Bone specific alkaline phosphatase
* Carboxyterminal cross-linking telopeptide
* Osteocalcin
* Tartrate-resistant acid phosphatase 5b
* 25-hydroxyvitamin D
* 1,25-hydroxyvitamin D
 |

ESRD, end-stage renal disease; FGF-23, fibroblast growth factor-23; HD, hemodialysis; iPTH, intact parathyroid hormone; PD, peritoneal dialysis